JAK1 and mature T-cell and NK-cell non-Hodgkin lymphoma: In a phase II study of R/R PTCL and mycosis fungoides, the JAK1/2 ruxolitinib showed modest efficacy in PTCL-NOS (ORR 18%, CR 9%), AITL/PTCL-TFH (ORR 33%, CR 11%), and ALCL (ORR 25%, CR 25%) [137].